This document provides adenovirus vectors and methods and materials related to using adenovirus vectors. For example, adenoviruses for delivering nucleic acid encoding one or more immunogens (e.g., one or more immunogens associated with a pathogen causing an infection) to cells within a mammal such that the mammal produces an effective immune response against the immunogen(s) are provided.

The invention relates to a recombinant Mycobacterium cell for use as an immunotherapeutic agent in the treatment of cancer, particularly in the treatment of solid tumors. More particularly, the invention relates to the immunotherapy of bladder carcinoma.

Simian adenoviral vectors are formulated with bioadhesives and excipients that maintain immunogenicity. They can be administered mucosally to provide effective prophylaxis and therapy.

The present invention relates to a veterinary vaccine containing nanoadjuvants in the form of emulsion and Clostridium difficile antigens, as well as the use of the vaccine in the preventions and treatment of a C. difficile infection, especially in birds and mammals. The object of the invention is also the use of this vaccine to produce C. difficile-specific antibodies.

Use of a superantigen in mucosal allergen specific immune therapy (ASIT) in a non-human mammal to enhance the effect thereof. In order to enhance the effect of the mucosal ASIT, the superantigen is mucosally administered before, or with, the allergen to the non-human mammal.

The present invention aims to provide a composition for promoting humoral immunity induction and a vaccine pharmaceutical composition that can be universally used for various antigens in inducing humoral immunity to antigens, contain a Th2 reaction promoter, and exerts a high humoral immunity inducing effect. The present invention relates to a vaccine pharmaceutical composition containing an antigen for humoral immunity induction and at least one Th2 reaction promoter.

The present invention relates to photon-irradiated streptococcal vaccine preparations and methods for their use.

Vaccines of preferential administration via mucous membranes, for the control of viral diseases generated by infectious agents that use heparan sulfate (HS) as a cellular receptor consisting of an immunogenic formulation for veterinary use, comprising an antigen whose cellular receptor is heparan sulfate (HS), a vehicle for oral, intranasal or parenteral administration, wherein said vehicle corresponds to D-glucosamine and functionalized N-acetyl-D-glucosamine biopolymers, with sulfur atoms, and/or functionalized chitosan biopolymer, with sulfur atoms, and where the antigen is microencapsulated by said types of functionalized biopolymers.

Provided herein are compositions and methods for vaccinating against infection with pathogenic Escherichia coli (E. coli). In some embodiments, the compositions may include a vaccine including an immunogenic portion of at least two E. coli proteins described herein.

Disclosed are synthetic nanocarrier compositions with coupled adjuvant compositions as well as related methods.